06:11 EDT Kenvue (KVUE) rallies 6% to $18 after Trump event on Tylenol risk
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KVUE:
- Barclays ‘rough math’ suggests Kenvue selloff overdone
- Citi sees Kenvue rallying on Trump’s lack of scientific evidence
- Hold Rating for Kenvue, Inc. Amidst Market Reaction to Government Advisories on Acetaminophen
- Kenvue Stock (KVUE) Pops, Defying Trump’s Claim Linking Tylenol to Autism
- Morning News Wrap-Up: Monday’s Biggest Stock Market Stories!